Literature DB >> 26802143

Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.

Diana Y Kircheva1, Aliya N Husain2, Sydeaka Watson3, Hedy L Kindler4, Amy Durkin1, Wickii T Vigneswaran5.   

Abstract

OBJECTIVES: The tumour/node/metastasis (TNM) staging system for malignant pleural mesothelioma (MPM) is a worldwide standard, but has many limitations. Tumour volume has been suggested as a predictor of survival. Due to the complex anatomy, estimation of tumour volume via CT scan can be challenging. Surgical volume may be more accurate. Therefore, we prospectively determined resected specimen volumes and weights in consecutive patients undergoing extended pleurectomy and decortication (EPD) and correlated this with overall survival and T and N stage.
METHODS: We evaluated 116 patients undergoing EPD for MPM in a single university centre over a 6-year period. All resected specimens were weighed, and the volume was measured by a fluid displacement method. A Cox regression model was used to identify significant predictors of survival; hazard ratios were calculated. A Kaplan-Meier method was used to summarize overall and subgroup survival. Logistic regression models were used to identify predictors of T and N stage.
RESULTS: There were 95 males and 21 females with a median age of 68 range 43-88 years. Forty-one patients had an ECOG performance status (PS) 0, 70 had 1 and 4 had 2. The median time between initial diagnosis and surgery was 134 days. Histology was epithelioid in 59, biphasic in 55 and sarcomatoid in 2. The mean volume was 641 ml with an SD of 393.34 ml. The median volume was 567.5 ml. The mean weight was 620.8 g with an SD of 361.92 g. The median weight was 552.0 g. Two-year survival from initial diagnosis and from EPD was 44 and 28%, respectively. PS (P = 0.002), epithelioid histology (P < 0.001), specimen weight (P < 0.001), volume (P < 0.001), platelet count (P = 0.015), T1 stage (P = 0.04) and adjuvant therapy (P = 01) were predictive of survival. Tumour volume was a predictor of T stage (P = 0.048) and survival (P = 0.03). There was no relationship between N stage and tumour volume, weight or histology.
CONCLUSIONS: PS, specimen weight, volume, epithelioid histology platelet count and adjuvant chemotherapy are significant predictors of survival in patients undergoing EPD for MPM. There is a correlation between specimen volume and T stage. These data suggest that tumour weight and volume may be valuable components for staging MPM.
© The Author 2016. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Extended pleurectomy and decortication; Malignant pleural mesothelioma; Outcomes; Staging; Tumour volume

Mesh:

Year:  2016        PMID: 26802143     DOI: 10.1093/ejcts/ezv422

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  8 in total

Review 1.  Malignant pleural mesothelioma: predictors and staging.

Authors:  William G Richards
Journal:  Ann Transl Med       Date:  2017-06

Review 2.  Volumetric assessment in malignant pleural mesothelioma.

Authors:  David J Murphy; Ritu R Gill
Journal:  Ann Transl Med       Date:  2017-06

3.  Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma.

Authors:  Wickii T Vigneswaran; Diana Y Kircheva; Adrian E Rodrigues; Sydeaka Watson; Amy Durkin Celauro; Berkley Rose; Hedy L Kindler; Aliya N Husain
Journal:  World J Surg       Date:  2018-04       Impact factor: 3.352

4.  Pleurectomy and decortication.

Authors:  Tedi Vlahu; Wicki T Vigneswaran
Journal:  Ann Transl Med       Date:  2017-06

Review 5.  Immunotherapy approaches for malignant pleural mesothelioma.

Authors:  Dean A Fennell; Sean Dulloo; James Harber
Journal:  Nat Rev Clin Oncol       Date:  2022-07-01       Impact factor: 65.011

6.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

Review 7.  Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group.

Authors:  Samuel G Armato; Kevin G Blyth; Jane J Keating; Sharyn Katz; Selina Tsim; Johan Coolen; Eyjolfur Gudmundsson; Isabelle Opitz; Anna K Nowak
Journal:  Lung Cancer       Date:  2016-09-05       Impact factor: 5.705

8.  Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment.

Authors:  Min Zhang; Jin-Li Luo; Qianqian Sun; James Harber; Alan G Dawson; Apostolos Nakas; Sara Busacca; Annabel J Sharkey; David Waller; Michael T Sheaff; Cathy Richards; Peter Wells-Jordan; Aarti Gaba; Charlotte Poile; Essa Y Baitei; Aleksandra Bzura; Joanna Dzialo; Maymun Jama; John Le Quesne; Amrita Bajaj; Luke Martinson; Jacqui A Shaw; Catrin Pritchard; Tamihiro Kamata; Nathaniel Kuse; Lee Brannan; Pan De Philip Zhang; Hongji Yang; Gareth Griffiths; Gareth Wilson; Charles Swanton; Frank Dudbridge; Edward J Hollox; Dean A Fennell
Journal:  Nat Commun       Date:  2021-03-19       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.